Gheath Al-Atrash MD, PhD

Gheath Al-Atrash MD, PhD

Dr. Gheath Al-Atrash, MD, PhD, serves as the esteemed leading physician scientist for our TZ102 T-cell therapy program. Currently, he practices therapeutic cell transplantation at The University of Texas MD Anderson Cancer Center, specifically in the Department of Stem Cell Transplantation and Cellular Therapy.

Rodger McEver, MD

Dr. McEver is a Distinguished Career Scientist and former Research VP at the Oklahoma Medical Research Foundation. He co-founded Targazyme Inc. and his groundbreaking research focuses on blood cell attachment. Roger, a world-renowned glycobiologist, is also a certified hematologist with extensive medical experience. He earned his medical degree from the University of Chicago.

Lijun Xia, MD, PhD

Dr. Xia is a renowned scientist and practicing hematologist/oncologist. As Chair of the Cardiovascular Department at the Oklahoma Medical Research Foundation, he holds the prestigious Merrick Foundation Chair in Biomedical Research. His research on O-glycans has led to the development of Targazyme‚Äôs promising candidates, TZ101 and TZ102. With a strong publication record and significant research… Continue reading Lijun Xia, MD, PhD

Alan J. Lewis, PhD

Dr. Lewis is the esteemed founding director of Targazyme, with extensive experience in the biotech industry. He has held key leadership positions in various companies, overseeing major financings and successful mergers. Dr. Lewis is a published author and holds a Ph.D. in pharmacology from the University of Wales and a medical degree from Yale University… Continue reading Alan J. Lewis, PhD